ECSP099776A - Moduladores de la gamma secretasa - Google Patents

Moduladores de la gamma secretasa

Info

Publication number
ECSP099776A
ECSP099776A EC2009009776A ECSP099776A ECSP099776A EC SP099776 A ECSP099776 A EC SP099776A EC 2009009776 A EC2009009776 A EC 2009009776A EC SP099776 A ECSP099776 A EC SP099776A EC SP099776 A ECSP099776 A EC SP099776A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
modulators
gamma
secretasa
Prior art date
Application number
EC2009009776A
Other languages
English (en)
Inventor
Anandan Palani
Zhaoning Zhu
John W Clader
Brian Mckittrick
William J Greenlee
Xianhai Huang
Mark D Mcbriar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP099776A publication Critical patent/ECSP099776A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En sus muchas realizaciones, la presente invención proporciona una novedosa clase de compuestos heterocíclicos de la fórmula: Fórmula Icomo moduladores de la gamma secretasa, métodos para la preparación de dichos compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos, métodos para la preparación de formulaciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos de tratamiento, prevención, inhibición, o alivio de una o más de varias enfermedades asociadas con la sistema nervioso central usando dichos compuestos o composiciones farmacéuticas.
EC2009009776A 2007-06-01 2009-12-01 Moduladores de la gamma secretasa ECSP099776A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94140507P 2007-06-01 2007-06-01
US98448407P 2007-11-01 2007-11-01

Publications (1)

Publication Number Publication Date
ECSP099776A true ECSP099776A (es) 2010-01-29

Family

ID=40084164

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009776A ECSP099776A (es) 2007-06-01 2009-12-01 Moduladores de la gamma secretasa

Country Status (18)

Country Link
US (1) US8426403B2 (es)
EP (1) EP2152695A2 (es)
JP (1) JP5495331B2 (es)
KR (1) KR20100037053A (es)
CN (1) CN101809016A (es)
AR (1) AR066152A1 (es)
AU (1) AU2008263207B2 (es)
BR (1) BRPI0812170A8 (es)
CA (1) CA2689948A1 (es)
CL (1) CL2008001560A1 (es)
CO (1) CO6241123A2 (es)
EC (1) ECSP099776A (es)
IL (1) IL202315A0 (es)
MX (1) MX2009013131A (es)
PE (1) PE20090363A1 (es)
RU (1) RU2009148866A (es)
TW (1) TW200914459A (es)
WO (1) WO2008153793A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677296A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
WO2010054067A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
AU2009314049B2 (en) 2008-11-13 2015-03-05 Merck Sharp & Dohme Corp. Gamma secretase modulators
CA2742472A1 (en) * 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
EP2379566A2 (en) * 2008-12-22 2011-10-26 Schering Corporation Gamma secretase modulators
WO2010147975A1 (en) * 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147969A2 (en) * 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443118A1 (en) * 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2015084752A1 (en) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
JP6628805B2 (ja) 2015-02-03 2020-01-15 ファイザー・インク 新規シクロプロパベンゾフラニルピリドピラジンジオン
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
WO2019167982A1 (ja) * 2018-02-28 2019-09-06 日本たばこ産業株式会社 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途
WO2020113077A1 (en) 2018-11-29 2020-06-04 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1065324A (en) * 1974-05-13 1979-10-30 E.R. Squibb And Sons 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles
CH594667A5 (en) * 1974-05-31 1978-01-13 Squibb & Sons Inc Hexahydro-2H-pyrazolo(4,3-C) pyridine derivs
US3979381A (en) * 1975-08-11 1976-09-07 E. R. Squibb & Sons, Inc. Thiopyrano[4,3-c] pyrazoles
US4003890A (en) * 1976-05-27 1977-01-18 E. R. Squibb & Sons, Inc. Benzylidene pyrano[4,3-c]pyrazoles
US4065617A (en) * 1977-02-04 1977-12-27 E. R. Squibb & Sons, Inc. 2-(2,2,2,-Trifluoroethyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridines
JP2002507603A (ja) * 1998-03-25 2002-03-12 ブリストル−マイヤーズ スクイブ カンパニー イミダゾロン食欲抑制薬：ｉ．非環式誘導体
PL358393A1 (en) * 2000-03-20 2004-08-09 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
WO2004071431A2 (en) 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2006001877A2 (en) 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005110422A2 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
CA2566094A1 (en) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
BRPI0618814A2 (pt) * 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
PL1992618T3 (pl) * 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
AR066151A1 (es) 2007-06-01 2009-07-29 Schering Corp Moduladores de gama secretasa
AU2009314049B2 (en) 2008-11-13 2015-03-05 Merck Sharp & Dohme Corp. Gamma secretase modulators

Also Published As

Publication number Publication date
RU2009148866A (ru) 2011-07-20
CL2008001560A1 (es) 2009-05-22
US20100256128A1 (en) 2010-10-07
US8426403B2 (en) 2013-04-23
PE20090363A1 (es) 2009-04-01
AU2008263207A2 (en) 2010-01-28
CN101809016A (zh) 2010-08-18
AU2008263207A1 (en) 2008-12-18
BRPI0812170A8 (pt) 2016-02-10
TW200914459A (en) 2009-04-01
KR20100037053A (ko) 2010-04-08
WO2008153793A3 (en) 2009-03-19
CO6241123A2 (es) 2011-01-20
BRPI0812170A2 (pt) 2014-12-02
JP5495331B2 (ja) 2014-05-21
WO2008153793A2 (en) 2008-12-18
CA2689948A1 (en) 2008-12-18
EP2152695A2 (en) 2010-02-17
MX2009013131A (es) 2010-01-15
AR066152A1 (es) 2009-07-29
AU2008263207B2 (en) 2013-10-03
IL202315A0 (en) 2010-06-30
JP2010529015A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
ECSP099776A (es) Moduladores de la gamma secretasa
ECSP099720A (es) Moduladores de gamma-secretasa
MX2010001506A (es) Moduladores de gamma secretasa.
EA201170772A1 (ru) Органические соединения
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
EA201100037A1 (ru) Органические соединения
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170832A1 (ru) Пуриновые соединения
MX2010003397A (es) Moduladores de la gamma secretasa.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
PA8855001A1 (es) Monocarbamas
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
ECSP099773A (es) Moduladores de gamma secretasa
MX2016006509A (es) Compuestos triciclicos de piperidina.
BRPI0620229A8 (pt) formulação